3 results about "Arterial Vasodilation" patented technology

The present invention discloses the use of 4-chloro-3-ethylphenol in the preparation of drugs for preventing or treating ulcerative colitis and sepsis, and relates to the field of biomedical technology. It is experimentally confirmed in the present invention that the ryanodine receptor (RyRs) agonist 4-chloro-3-ethylphenol has significant effects in preventing or treating ulcerative colitis and sepsis, and 4-chloro-3-ethylphenol is a clinically potential drug for the preparation of drugs for preventing or treating ulcerative colitis and sepsis; meanwhile, using 4-chloro-3-ethylphenol as a reliable tool can clearly distinguish the two components of store-operated calcium channels (SOCE), that is, inducing ER / Ca<supgt;2+< / supgt; release through RyR, but blocking the entry of Ca<supgt;2+< / supgt; through SOC in vascular endothelial cells, having a dual effect; further experiments confirm that pure endothelial cell RyR / ER / Ca<supgt;2+< / supgt> release is a unique pathway for regulating EDH-mediated arterial vasodilation in a healthy state and has an anti-inflammatory effect on ulcerative colitis and sepsis.

The application belongs to the technical field of medicine, and particularly relates to application of acacetin or 6-hydroxyflavone in preparation of anti-angina pectoris drugs, and aims to solve the problems of adverse reactions such as blood pressure drop, reflex tachycardia and the like caused by non-selective vasodilation of existing anti-angina pectoris drugs, wherein the drug improves myocardial blood supply by selectively dilating coronary vessels of the heart, wherein acacetin dilates coronary vessels of the heart by inhibiting cardiac coronary vessel myosin light chain kinase and activating myosin light chain phosphatase, and 6-hydroxyflavone dilates coronary vessels of the heart by inhibiting protein kinase C and enhancing myosin light chain phosphatase activity; and the acacetin or 6-hydroxyflavone significantly reduces the symptoms of myocardial ischemia of rats caused by isopropyl adrenaline, improves characteristic ECG abnormal changes of angina pectoris, does not affect heart rate and systemic blood pressure, and is safer, thereby providing a potential drug selection for anti-angina pectoris treatment.

The invention discloses application of 4-chloro-3-ethyl phenol in preparation of a medicine for preventing or treating ulcerative colitis and septicopyemia, and relates to the technical field of biological medicine. Experiments prove that the raney receptor (RyRs) agonist 4-chloro-3-ethyl phenol has a remarkable effect on preventing or treating ulcerative colitis and septicopyemia, and the 4-chloro-3-ethyl phenol is a clinical potential medicine for preventing or treating ulcerative colitis and septicopyemia; meanwhile, 4-chloro-3-ethylphenol is used as a reliable tool, two components of a calcium channel (SOCE) controlled by a calcium pool can be clearly distinguished, that is, ER / Ca < 2 + > release is induced through RyR, but Ca < 2 + > passing through SOC in vascular endothelial cells is blocked from entering, and dual effects are achieved; further experiments prove that pure endothelial cell RyR / ER / Ca < 2 + > release is a unique way for regulating EDH-mediated artery vasodilation in a healthy state, and has an anti-inflammatory effect on ulcerative colitis and septicopyemia.